Medical devices — US PTAB Patent Cases
522 decisions indexed
Page 4 of 18 · 522 total
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care has filed an IPR petition challenging Inari Medical's 11,865,291 patent covering hemostasis valves. The petitioner asserts anticipation and obviousness based on Schaffer and its combinations with Hartley, Eller, and Garrison. The Board must decide whether to institute the review.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care successfully challenged the patentability of Inari Medical's hemostasis valve claims before the PTAB, leading to institution on grounds of anticipation and obviousness. The Board focused heavily on claim construction, ultimately defining 'filament' as a flexible length of material necessary for the device function. This decision sets important precedent regarding functional limitations in medical device patents.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that all nine claims of Inari Medical’s hemostasis‑valve patent are unpatentable, finding anticipation and obviousness over Schaffer and its combinations with Hartley, Eller, and Garrison.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s U.S. Patent 12,016,580 covering intravascular embolism treatment devices after finding Imperative Care’s obviousness arguments sufficiently promising.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB granted institution of an IPR against Inari Medical’s 12,016,580 hemostasis valve patent, finding a reasonable likelihood that Imperative Care will prevail on at least one of the nine challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s hemostasis valve patent after finding Imperative Care’s likelihood of success sufficient. All nine claims are now under trial.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care has filed an IPR petition seeking to invalidate Inari Medical’s 12,016,580 clot‑removal patent. The petition relies on Garrison and several other catheter‑related references to argue anticipation and obviousness under §§102 and 103. The Board has yet to decide whether to institute the review.
Samsung Electronics Co., Ltd. et al. v.Netlist, Inc.
The PTAB initiated a sua sponte Director Review of an IPR institution after the ITC found the challenged claims valid and commercially successful, resulting in a stay of the IPR pending further opinion.
Samsung Electronics Co., Ltd. et al. v.Netlist, Inc.
The PTAB initiated a sua sponte Director Review of an IPR involving Sinclair Pharma and others versus Hydrafacial, staying the proceeding after the ITC affirmed the claims’ validity and commercial success.
Aesthetic Management Partners, LLC et al. v.HydraFacial LLC
Aesthetic Management Partners has filed an IPR petition seeking cancellation of all 20 claims of HydraFacial’s ’477 skin‑treatment patent. The petition relies on obviousness grounds under §103, citing multiple prior‑art references covering microdermabrasion and fluid delivery systems.
Aesthetic Management Partners, LLC et al. v.HydraFacial LLC
The USPTO granted institution for IPR2025-01217, allowing the trial to proceed after determining the petitioner had a reasonable likelihood of prevailing. This decision is part of a larger set of institutional rulings.
Ascentcare Dental Products, Inc. v.Solmetex, LLC
Ascentcare Dental Products has petitioned the PTAB to invalidate claims 1‑4 and 7‑18 of Solmetex’s 11,589,970 patent, alleging obviousness over several prior‑art dental mouthpiece references. The petition seeks institution of an IPR and cancellation of the challenged claims.
Ascentcare Dental Products, Inc. v.Solmetex, LLC
Ascentcare Dental Products has filed an IPR petition challenging Solmetex’s intraoral device patent, asserting that all claims 12‑21 are obvious over prior art. The petition relies on Park, Baughan, Johnson and Hirsch references and seeks cancellation of the claims.
Ascentcare Dental Products, Inc. v.Solmetex, LLC
Ascentcare Dental Products petitions the PTAB to invalidate Solmetex’s 11,589,969 intraoral mesh patent. The petition alleges anticipation and obviousness over five prior‑art references covering all independent and dependent claims.
Aerin Medical Inc. v.Neurent Medical Ltd. et al.
Aerin Medical seeks IPR cancellation of Neurent’s ’974 nasal neuromodulation patent, asserting that all 20 claims are obvious over Townley, Wolf‑003/Wolf‑290, and the Angeles console.
Aerin Medical Inc. v.Neurent Medical Ltd. et al.
Aerin Medical has petitioned the PTAB to invalidate claims 1‑30 of Neurent’s ’973 patent, arguing obviousness over Townley and Wolf‑003/Wolf‑290 disclosures. The petition seeks institution and cancellation of the claims.
Ascentcare Dental Products, Inc. v.Solmetex, LLC
Ascentcare Dental Products has petitioned the PTAB to invalidate Solmetex’s 11,589,970 dental mouthpiece patent, asserting that all challenged claims are obvious over prior‑art references such as Park, Baughan, Johnson, Black and Hirsch.
Ascentcare Dental Products, Inc. v.Solmetex, LLC
Ascentcare Dental Products petitions the PTAB to invalidate 18 claims of Solmetex’s 2023 intraoral mesh patent, asserting anticipation and obviousness over five earlier dental mouthpiece references. The petition seeks institution of an IPR and cancellation of the challenged claims.
Ascentcare Dental Products, Inc. v.Solmetex, LLC
Ascentcare Dental Products has filed an IPR petition challenging ten claims of Solmetex’s intraoral device patent, alleging obviousness over multiple prior‑art references. The petition seeks cancellation of claims 12‑21 and argues that the patent owner broadened claim scope after product launch.
Aerin Medical Inc. v.Neurent Medical Ltd. et al.
Aerin Medical seeks IPR cancellation of Neurent's U.S. Patent 12,089,889 covering a nasal neuromodulation device, asserting obviousness over four prior‑art references and lack of written description.
Ascentcare Dental Products, Inc. v.Solmetex, LLC
Ascentcare Dental Products has filed a post‑grant review petition seeking cancellation of all 31 claims of Solmetex’s dental mouthpiece patent, alleging obviousness, lack of written description, and indefiniteness. The petition leans on three earlier patents and expert testimony to argue the claims are unpatentable.
Aerin Medical Inc. v.Neurent Medical Ltd. et al.
Aerin Medical has filed an IPR petition seeking cancellation of all 20 claims of Neurent’s ’262 patent, arguing they are obvious over four prior‑art references covering nasal neuromodulation technology.
Solventum Corporation v.Wound Healing Technologies Corp.
Solventum Corp. has filed an IPR petition seeking to invalidate all 13 claims of Wound Healing Technologies' wound‑dressing patent. The petition argues the claims are obvious over prior‑art references such as Argenta, Hu, Biggie and Lockwood.
Solventum Corporation v.Wound Healing Technologies Corp.
The PTAB granted institution for IPR2025-01042, allowing Solventum Corporation to challenge Wound Healing Technologies Corp.'s patent 10639404 after finding a reasonable likelihood of prevailing.
Ascentcare Dental Products, Inc. v.Solmetex, LLC
Ascentcare Dental Products has filed an IPR petition challenging Solmetex’s 11,826,217 dental mouthpiece patent, asserting that the claims are obvious over prior patents by Nguyen, Black, and Hirsch. The petition requests institution and cancellation of claims 1‑11 and 13‑23.
Shenzhen Root Technology Co., Ltd. et al. v.Willow Blossom Holdco Limited et al.
Shenzhen Root Technology petitions to invalidate U.S. Patent 11,806,454 covering a wearable breast pump, arguing the claims are obvious over a suite of prior‑art references.
Shenzhen Root Technology Co., Ltd. et al. v.Willow Blossom Holdco Limited et al.
Shenzhen Root Technology Co., Ltd. successfully had its Inter Partes Review petition instituted against Willow Blossom Holdco Limited for infringing on breast pump system patents. The Board found sufficient evidence to proceed with the obviousness claims, allowing the case to move forward to trial.
Ascentcare Dental Products, Inc. v.Solmetex, LLC
Ascentcare Dental Products has petitioned the PTAB to review U.S. Patent 11,589,969, asserting that its claims are anticipated or obvious over earlier dental mouthpiece patents. The petition outlines five statutory grounds under §§102(b) and 103, targeting claims 1‑4 and 6‑19 for cancellation.
Ascentcare Dental Products, Inc. v.Solmetex, LLC
Ascentcare Dental Products has filed an IPR petition challenging Solmetex’s 2023 intraoral mesh patent, alleging anticipation and obviousness over five prior‑art references. The petition seeks cancellation of 18 claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that all nine claims of Inari Medical’s hemostasis valve patent are unpatentable, finding anticipation and obviousness over Schaffer and combinations with Hartley, Eller, and Garrison.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.